Abstract
We investigated the susceptibility of five human glioma cell lines toanti-Fas antibody. All human glioma cells tested constitutively expressedFas antigen on their surfaces and the level of the expression variedslightly in each cell line. The cells had a low susceptibility to anti-Fasantibody-mediated apoptosis. There were four moderately resistant cell lines(U251-SP, U251-MG, SK-MG-1, T98) and one highly resistant cell line (U251nu/nu). For this study we prepared liposomes containing anti-Fas antibodyand studied the augmentation of the antibody-mediated apoptosis. Theliposomes induced apoptosis significantly more often than did anti-Fasantibody alone. These results indicate that anti-Fas antibody-mediatedapoptosis does not require a critical level of cell surface expression ofFas antigen but rather depends on the intensity of Fas signal transduction.
This is a preview of subscription content, log in via an institution to check access.
References
Yoshida J, Kajita Y, Wakabayashi T, Sugita K: Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127: 55–59, 1994
Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747–1756, 1989
Schulze-Osthoff K, Krammer PH, Droge W: Divergent signaling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 13: 4587–4596, 1994
Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178, 1993
Weller M, Frei K, Groscurth PH, Yonekawa Y, Fontana A: Anti-Fas antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954–964, 1994
Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas gene transfer for human malignant glioma. Cancer Res 55: 2936–2944, 1995
Yagi K, Noda H, Kurono M, Ohishi N: Efficient gene transfer with less than cytotoxicity by means of cationic multilamellar liposomes. Biochem Biophys Res Commun 196: 1042–1048, 1993
Yoshida J, Mizuno M: Simple preparation and characterization of cationic liposomes associated with a monoclonal antibody against glioma-associated antigen (immunoliposomes). J Liposome Res 5: 981–995, 1995
Kato K, Yoshida J, Mizuno M, Sugita K, Emi N: Retroviral transfer of herpes simplex thymidine kinase gene into glioma cells caused targeting of gancyclovir cytotoxic effect. Neurol Med Chir (Tokyo) 34: 339–344, 1994
Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizaka T, Yagi K: Growth inhibition of glioma cells transfected with the human ?-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50: 7826–7829, 1990
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608, 1993
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivowith a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609–619, 1993
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994
Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: Levels of Fas and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580–1586, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohta, S., Mizuno, M., Takaoka, T. et al. Augmentation of anti-Fas antibody-mediated apoptosis on human glioma cells by liposomes associated with the antibody. J Neurooncol 35, 7–11 (1997). https://doi.org/10.1023/A:1005843600950
Issue Date:
DOI: https://doi.org/10.1023/A:1005843600950